ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY RATIONALES FOR NURSING PRACTICE
, ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
c c c c c c c c
1. Acwomancdiagnosedcwithcobsessive–
compulsivecdisorderchascbeencprescribedcoralc paroxetinechydrochloride.c Whatc iscthec
expectedceffectcforcthiscprescription?
A. Curativeceffectconcsymptoms
B. Systemicceffectconcsymptoms
C. Localceffectconcsymptoms
D. Parenteralceffectconcsymptoms
ANS:ccB
Rationale:cDrugscthatcproducecsystemicceffectscarectakencintocthecbody,ccirculatedcthroughc thecbl
oodstreamctoctheircsitescofcactioncincvariouscbodyctissues,candceventuallyceliminatedc fromcthecbod
y.cCurativecagentscarecgivenctoccurecacdiseasecprocess.cIncthisccase,cparoxetinec hydrochloridecwil
lccontrolcthecsymptomscbutc notccurecthecdisorder.cDrugscwithclocalceffects,c suchcascsunscreencandcloc
alcanesthetics,cactcmainlycatcthecsitecofcapplication.c Paroxetinec hydrochlorideciscnotcadministered
cparenterally.c Parenteralcagentscarecadministeredc subcutaneously,c intramuscularly,c orcintraveno
usly.
PTS: 1 REF: p.c3,cIntroduction OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc TOP
: Chapter:c1:cThecFoundationcofcPharmacology:c QualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:cc CognitivecLevel:cUnderstand NOT:c MultiplecChoice
2. Acclientchascbeencprescribedcancantibiotic.cThiscmedicationciscacnaturallycoccurring
substancecthatchascbeenccheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOtcM
.C iscanothercnamecforcthisctypecofcmedication?
A. Syntheticcdrug
B. Semisyntheticcdrug
C. Biotechnologycdrug
D. Prototypecdrug
ANS:ccB
Rationale:cSemisyntheticcdrugsc(e.g.,cmanycantibiotics)carec naturallycoccurringcsubstancesc thatcha
vecbeencchemicallycmodified.cSyntheticcdrugscarecmorecstandardizedcinctheircchemicalc characteri
stics,c morecconsistentcinctheirceffects,candclessclikelyctocproducecallergiccreactions.c Biotechnologycd
rugscinvolvecmanipulatingcDNAcandcRNAcandcrecombiningcgenescintoc hybridcmoleculescthatccanc
becinsertedcintoclivingcorganisms.cPrototypecdrugscarecthecfirstc drugcofcacparticularcgroupctocbecd
eveloped.
PTS: 1 REF: p.c3,cDrugcSources OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc TOP
: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:cc CognitivecLevel:cUnderstand NOT:c MultiplecChoice
3. Whichcclassificationcappliesctocmorphine?
A. Centralcnervouscsystemcdepressant
B. Centralcnervouscsystemcstimulant
ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
,ABRAMS' CLINICAL DRUG THERAPY RATIONALES FOR NURSING PRACTICE
,ABRAMS' CLINICAL DRUG THERAPY RATIONALES FOR NURSING PRACTICE
, ABRAMS' CLINICAL DRUG THERAPY: RATIONALES FOR NURSING PRACTICE
Chapter 1, The Foundation of Pharmacology: Quality and Safety
c c c c c c c c
1. Acwomancdiagnosedcwithcobsessive–
compulsivecdisorderchascbeencprescribedcoralc paroxetinechydrochloride.c Whatc iscthec
expectedceffectcforcthiscprescription?
A. Curativeceffectconcsymptoms
B. Systemicceffectconcsymptoms
C. Localceffectconcsymptoms
D. Parenteralceffectconcsymptoms
ANS:ccB
Rationale:cDrugscthatcproducecsystemicceffectscarectakencintocthecbody,ccirculatedcthroughc thecbl
oodstreamctoctheircsitescofcactioncincvariouscbodyctissues,candceventuallyceliminatedc fromcthecbod
y.cCurativecagentscarecgivenctoccurecacdiseasecprocess.cIncthisccase,cparoxetinec hydrochloridecwil
lccontrolcthecsymptomscbutc notccurecthecdisorder.cDrugscwithclocalceffects,c suchcascsunscreencandcloc
alcanesthetics,cactcmainlycatcthecsitecofcapplication.c Paroxetinec hydrochlorideciscnotcadministered
cparenterally.c Parenteralcagentscarecadministeredc subcutaneously,c intramuscularly,c orcintraveno
usly.
PTS: 1 REF: p.c3,cIntroduction OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc TOP
: Chapter:c1:cThecFoundationcofcPharmacology:c QualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:cc CognitivecLevel:cUnderstand NOT:c MultiplecChoice
2. Acclientchascbeencprescribedcancantibiotic.cThiscmedicationciscacnaturallycoccurring
substancecthatchascbeenccheGmRicA
alDlyEm
SoBdOifOieSd.TWhaOtcM
.C iscanothercnamecforcthisctypecofcmedication?
A. Syntheticcdrug
B. Semisyntheticcdrug
C. Biotechnologycdrug
D. Prototypecdrug
ANS:ccB
Rationale:cSemisyntheticcdrugsc(e.g.,cmanycantibiotics)carec naturallycoccurringcsubstancesc thatcha
vecbeencchemicallycmodified.cSyntheticcdrugscarecmorecstandardizedcinctheircchemicalc characteri
stics,c morecconsistentcinctheirceffects,candclessclikelyctocproducecallergiccreactions.c Biotechnologycd
rugscinvolvecmanipulatingcDNAcandcRNAcandcrecombiningcgenescintoc hybridcmoleculescthatccanc
becinsertedcintoclivingcorganisms.cPrototypecdrugscarecthecfirstc drugcofcacparticularcgroupctocbecd
eveloped.
PTS: 1 REF: p.c3,cDrugcSources OBJ: 1
NAT:c ClientcNeeds:cPhysiologicalcIntegrity:cPharmacologicalcandcParenteralcTherapiesc TOP
: Chapter:c1:cThecFoundationcofcPharmacology:cQualitycandcSafety
KEY:c IntegratedcProcess:cNursingcProcess
BLM:cc CognitivecLevel:cUnderstand NOT:c MultiplecChoice
3. Whichcclassificationcappliesctocmorphine?
A. Centralcnervouscsystemcdepressant
B. Centralcnervouscsystemcstimulant
ABRAMS'cCLINICALcDRUGcTHERAPY:cRATIONALEScFORcNURSINGcPRACTICE
